Self-amplifying RNA COVID-19 vaccine

Christopher J Wayne; Anna K Blakney

doi:10.1016/j.cell.2024.03.018

Self-amplifying RNA COVID-19 vaccine

Cell. 2024 Apr 11;187(8):1822-1822.e1. doi: 10.1016/j.cell.2024.03.018.

Authors

Christopher J Wayne¹, Anna K Blakney²

Affiliations

¹ Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, BC, Canada.
² Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, BC, Canada. Electronic address: anna.blakney@msl.ubc.ca.

PMID: 38608649
DOI: 10.1016/j.cell.2024.03.018

Abstract

In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.

MeSH terms

BNT162 Vaccine
COVID-19 / prevention & control
COVID-19 Vaccines*
Humans
mRNA Vaccines* / administration & dosage
mRNA Vaccines* / adverse effects

Substances

BNT162 Vaccine
COVID-19 Vaccines
mRNA Vaccines
ARCT-154 vaccine